Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 7/20 | 0.52 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 2/20 | 0.45 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1600161 | 0.81 | BRD4 (0.49) | MAPK14CD274EPHX2KDR | |
| SCHEMBL1801810 | 0.80 | CD274 (0.62) | MAPK14CD274EPHX2KDR | |
| SCHEMBL4256695 | 0.79 | EPHX2 (0.74) | EPHX2 | |
| SCHEMBL10130045 | 0.79 | MAPK14 (0.60) | MAPK14KDR | |
| SCHEMBL5257397 | 0.79 | MAPK14 (0.65) | MAPK14KDR | |
| SCHEMBL6814510 | 0.77 | KDR (0.62) | CD274EPHX2HTR2AKDR | |
| SCHEMBL2087287 | 0.77 | SYK (0.51) | MAPK14CD274KDR | |
| SCHEMBL20518810 | 0.77 | CD274 (0.49) | MAPK14CD274EPHX2HTR2AHTR2C | |
| SCHEMBL5559654 | 0.76 | RXFP1 (0.54) | MAPK14CD274CNR1CNR2RXFP1 | |
| SCHEMBL14100169 | 0.76 | CD274 (0.55) | CD274EPHX2HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7919617-B2 | Cytokine inhibitors | iTherX Pharmaceuticals Inc. (US) | 2011-04-05 | — | — | US | disclosed |
| US-7897599-B2 | Cytokine inhibitors | iTherX Pharmaceuticals Inc. (US) | 2011-03-01 | — | — | US | disclosed |
| US-20100273797-A1 | ALPHA-KETOAMIDES AND DERIVATIVES THEREOF | ITHERX PHARMACEUTICALS, INC. | 2010-10-28 | — | — | US | disclosed |
| US-7749999-B2 | Alpha-ketoamides and derivatives thereof | ITHERX PHARMACEUTICALS, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| US-20100093734-A1 | CYTOKINE INHIBITORS | ITHERX PHARMACEUTICALS, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-20100093735-A1 | CYTOKINE INHIBITORS | ITHERX PHARMACEUTICALS, INC. (US) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093734-A1 | CYTOKINE INHIBITORS | TNF, IL1RN, IL1A | MAPK14 371/4885CD274 397/4885EPHX2 827/4885 |
| US-20100273797-A1 | ALPHA-KETOAMIDES AND DERIVATIVES THEREOF | TNF, IL1A, IL1B | MAPK14 696/4885CD274 3648/4885EPHX2 504/4885 |
| US-20100093735-A1 | CYTOKINE INHIBITORS | TNF, IL1RN, IL1A | MAPK14 371/4885CD274 397/4885EPHX2 827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.